Comparative Study of Lipid and Glycemic Effects of Pioglitazone, Rosiglitazone with Glibenclamide in Patients with Type 2 Diabetes and Dyslipidemia

Objective: To evaluate the lipid and glycemic effects of Thiazolidinedione group of drugs (Pioglitazone, Rosiglitazone) in Type 2 diabetic patients with dyslipidemia.Methodogy: After ethical clearance and informed consent Type 2 diabetic patients with dyslipidemia attending the diabetic out patient clinic of Diabetology unit of Voluntary health services hospital.Chennai were screened and 45 patients selected for the study according to WHO criteria for diabetes and National cholesterol Education program guidelines for dyslipidemia. Each group consisting of 15 patients viz., Group I: Received Glibenclamide 5 mg/day. Group II: Received Pioglitazone 15 mg/day. Group III: Received Rosiglitazone 4 mg/day. Estimation of serum Total Cholesterol and HDL Cholesterol,Triglycerides,VLDL, Blood glucose,SGOT,S.GPT levels were estimated. Anthropometric evaluation and clinical parameters also evaluated. Results and discussion: Pioglitazone group showed significant reduction (p < 0.05) in fasting and post prandial blood glucose level at 12 week of study th when compared with sulphonylurea group. Reduction in total cholesterol level. 16% in pioglitazone, 4% in rosiglitazone and 1% in sulphonylurea group. Serum Triglycerides showed significant reduction (P< 0.001) in Rosiglitazone group when compared to sulphonylurea group at 12 week of the study. HDL cholesterol level th showed significant increase (p < 0.001) in pioglitazone group when compared to sulphonylurea group in 8 th showed significant increase in SGOT and SGPT levels (p < 0.001) in pioglitazone as well as rosiglitazone group. Conclusion:Thiazolidinediones group of oral antidiabetic drugs shows hypoglycemic as well as favourable lipidemic effects on type 2 diabetic patients. Among the two glitazones, pioglitazone showed more favourable effects of increasing HDL cholesterol. Hence this group of drugs may be considered for use in the early stage of Type 2 diabetes judiciously to tide over the insulin resistance, hyperglycemia and dyslipidemia and thereby to prevent cardiovascular morbidity.